Galderma to expand manufacturing and innovation footprint in the APAC

Flemming Ørnskov, Chief Executive Officer at GALDERMA

Reaffirming its bold ambition to become the leading dermatology company in the world, Galderma announced its intention to expand its manufacturing and innovation footprint in the Asia-Pacific region, with support from the Singapore Economic Development Board.

What is the growth rate of Galderma?

Galderma intends to explore opportunities to build a fifth manufacturing plant with a high degree of digitalization and automation in Singapore in response to growing consumer demand and to support long-term sustainable growth over the coming years.

With its premiumization strategy and broad channel exposure, Galderma is well positioned to capitalize on growing consumer demand across Asia-Pacific, where the market has remained on a consistent growth trajectory, with robust demand for premium science-based products.

Galderma’s manufacturing plant in Singapore is expected to increase the firm’s total capacity for Dermo-cosmetics premium brand production by up to 350 million units a year, in line with anticipated growth in the region. The news comes as part of its strategic manufacturing roadmap, aligned with the company’s unique Integrated Dermatology Strategy.

Following a record 2021 performance, Galderma has showed strong commercial and financial performance in the first half of 2022, with continued growth across product categories. Dermo-cosmetics has grown by 31% YoY on a constant currency basis, fueled by the strong performance of Cetaphil® driven by e-commerce and launches in China and the rest of Asia.

What were the executives’ thoughts on the expansion?

“Our goal is to support our strong growth trajectory in the long-term with a new manufacturing plant that will significantly increase our capacity to serve consumers with premium brands from our differentiated Dermo-cosmetics portfolio across geographies, and primarily throughout our key markets in Asia-Pacific,” Flemming Ørnskov, CEO at GALDERMA.

“We sincerely thank the Economic Development Board of Singapore for its support, and we look forward to further collaboration to bring this exciting project to life,” Flemming said.

“We welcome Galderma’s expansion in Singapore, driven by the need to meet growing demand,” Tan Kong Hwee, Executive Vice President at Economic Development Board.

“This adds to the growing number of consumer healthcare companies that use Singapore as a hub for innovation. We are also pleased that Galderma’s first Dermo-cosmetics manufacturing plant in Asia will be landing in Singapore, as it will leverage and contribute to Singapore’s advanced manufacturing capabilities. There will be many exciting innovation and manufacturing job opportunities that Galderma will create with this investment.”

Galderma benefits from a presence in Singapore, which is not only a key market for Galderma’s innovative portfolio of cutting-edge brands, but also serves as its APAC hub.